Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.
Learn more about biosimilars and their benefits for patients and healthcare systems.
The Government of Ontario spending $3 million more than it needs to on biologic drugs every single week. Biosimilars are the solution, writes Biosimilars Canada President Jim Keon in his op-ed for QP Briefing.
Effective October 1, 2021, adult patients who take NovoRapid insulin aspart will be required to switch to a biosimilar version by April 1, 2022. All new patient starts for insulin aspart will be covered for a biosimilar.